Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.

Northwestern Medicine scientists have uncovered new details about the genetic structure of ovarian cancer stem cells, ...

A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...

Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, ...

Hammond’s lab has previously shown that IL-12 delivered by layer-by-layer nanoparticles can activate key immune cells and ...

Results from a new Phase 3 trial published in the journal npj Precision Oncology found that a cancer stem cell test can ...

To optimize treatment outcomes for patients whose late-stage cancer shows resistance to the standard treatment, Sarasota Memorial Research Institute will participate in testing an experimental ...

Chemotherapy regimens chosen by the ChemoID assay dramatically increased ORR in patients with platinum-resistant ovarian ...

Carnegie Mellon University’s Summer Undergraduate Research Fellowship (SURF) program provides funding for undergraduates to work full time on research projects during the summer. Many students ...

Antibody-drug conjugates and their development remains a central theme in ongoing research within the realm of ovarian cancer ...

A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.